Danaher Corporation logo

DHR

Danaher Corporation
NYSE
Healthcare
Diagnostics & Research
danaher.com
$.
$6.79(-3.18%)
LIVEupdated just now
O: $214.74H: $214.34L: $206.59

Market Cap

$145.36B

P/E Ratio

36.79

52W High

$242.80

52W Low

$160.93

C

Quality Score

DHR scores 69/100 (C) — dividend safety is the strongest factor, valuation the weakest.

69

/ 100

See the full 7-factor breakdown with PRO.

Upgrade
More historical data is needed for full RSI, MACD, and Bollinger readings.

AI Technical Interpretation

PRO turns DHR's RSI, MACD, moving averages, and Bollinger Bands into a plain-English read on trend, momentum, and volatility - context, not predictions.

Upgrade to PRO

AI “Why Did It Move?”

Get a ranked, evidence-grounded read on what's likely driving DHR's move today — news, earnings, analyst activity, sector context, and technicals combined.

Upgrade to PRO

Analyst Ratings
26 analysts

ConsensusStrong Buy
Strong Buy5
Buy17
Hold4
Sell0
Strong Sell0
Avg price target+10.25%
$227.96from $206.77
Low $195.00Median $230.00High $310.00

Consensus & price targets via Yahoo Finance & Financial Modeling Prep. Not investment advice.

AI Fair Value Estimate

Get an AI analyst's take on whether DHR looks cheap or expensive — a fair-value range with plain-English reasoning, in one click.

Upgrade to PRO

AI Earnings Preview

Next report 2026-10-20 · in 49 days

Consensus estimates

EPS

$1.92

Revenue

$6.56B

Recent EPS surprises

2026-06Beat +5%2026-03Beat +6%2025-12Beat +2%2025-09Beat +10%

Unlock the AI preview for DHR

Get an AI analyst's read on the setup, what to watch, and risks heading into the print.

Upgrade to PRO
Post-Earnings Recap· reported 2026-06-30

Unlock the post-earnings recap for DHR

Get an AI analyst's read on how the report went and how the stock reacted.

Upgrade to PRO

Dividend
Quarterly

Forward yield

0.77%

Annual / share

$1.60

Last ex-date

Jun 26, 2026

Last payment

Jul 31, 2026

Recent payments

Ex-date Jun 26, 2026$0.40
Ex-date Mar 27, 2026$0.40
Ex-date Dec 26, 2025$0.32
Ex-date Sep 26, 2025$0.32
Ex-date Jun 27, 2025$0.32
Ex-date Mar 28, 2025$0.32
Ex-date Dec 27, 2024$0.27
Ex-date Sep 27, 2024$0.27

Forward annual dividend from the declared rate (or latest payment × frequency) · via Yahoo Finance & Financial Modeling Prep.

AI Dividend Safety

Get an AI read on whether DHR's dividend looks sustainable — earnings coverage, payout history, and the risks worth researching.

Upgrade to PRO

Insider Trading
50 recent filings

Buys

39

Sells

11

Reported value

$14.50M

50 shown
DateInsiderTypeSharesPriceValueOwned
Aug 21, 2026

BLAIR, RAINER

Director, President & CEO

Sell7,755$219.35$1.70M-
Aug 21, 2026

BLAIR, RAINER

Director, President & CEO

Sell11,307$217.77$2.46M-
Aug 21, 2026

BLAIR, RAINER

Director, President & CEO

Sell39,193$218.73$8.57M-
Aug 4, 2026

RILEY, CHRISTOPHER PAUL

Executive Vice President

Buy41,072$0.00$0.00-
Aug 4, 2026

GUGINO, MATTHEW E

EVP & Chief Financial Officer

Buy153,563$0.00$0.00-
Aug 4, 2026

GUTIERREZ-RAMOS, JOSE-CARLOS

SVP, Chief Science Officer

Buy13,477$0.00$0.00-
Aug 4, 2026

SAWYER, MONTGOMERY JULIE A

Executive Vice President

Buy245,701$0.00$0.00-
Aug 4, 2026

BOUDA, CHRISTOPHER

VP, Chief Accounting Officer

Buy12,286$0.00$0.00-
Aug 4, 2026

RALES, MITCHELL P

Director, Chairman of Exec. Committee

Buy500,000$0.00$0.00-
Aug 4, 2026

RALES, MITCHELL P

Director, Chairman of Exec. Committee

Buy1,000,000$0.00$0.00-
Aug 4, 2026

RALES, STEVEN M

Director, Chairman

Buy1,000,000$0.00$0.00-
Aug 4, 2026

RALES, STEVEN M

Director, Chairman

Buy500,000$0.00$0.00-
Aug 4, 2026

LEIKEN, JONATHAN

SVP-Chief Legal Officer

Buy92,138$0.00$0.00-
Aug 4, 2026

MILOSEVICH, GREGORY M

Executive Vice President

Buy15,402$0.00$0.00-
Jul 31, 2026

LIST, TERI

Director

Buy16$194.98$3,064.31-
Jul 31, 2026

FILLER, LINDA

Director

Buy18$194.98$3,574.57-
Jul 31, 2026

ZERHOUNI, ELIAS A.

Director

Buy237$194.98$46,138.70-
Jul 31, 2026

STEVENS, RAYMOND C

Director

Buy182$194.98$35,398.42-
Jul 31, 2026

DEWAN, FEROZ

Director

Buy171$194.98$33,379.60-
Jul 31, 2026

SANDERS, A SHANE

Director

Buy211$194.98$41,180.75-
Jul 31, 2026

SPOON, ALAN G

Director

Buy230$194.98$44,825.12-
Jul 15, 2026

FILLER, LINDA

Director

Sell1,181$200.79$237,132.99-
Jul 15, 2026

FILLER, LINDA

Director

Buy3,298$71.88$237,060.24-
Jul 15, 2026

BOUDA, CHRISTOPHER

VP, Chief Accounting Officer

Sell60$200.79$12,047.40-
Jul 15, 2026

ZERHOUNI, ELIAS A.

Director

Sell1,181$200.79$237,132.99-
Jul 15, 2026

FILLER, LINDA

Director

Sell3,298$0.00$0.00-
Jul 15, 2026

ZERHOUNI, ELIAS A.

Director

Sell3,298$0.00$0.00-
Jul 15, 2026

ZERHOUNI, ELIAS A.

Director

Buy3,298$71.88$237,060.24-
May 15, 2026

SANDERS, A SHANE

Director

Buy1,699$0.00$0.00-
May 15, 2026

DEWAN, FEROZ

Director

Buy680$0.00$0.00-
May 15, 2026

ZERHOUNI, ELIAS A.

Director

Buy1,699$0.00$0.00-
May 15, 2026

ZERHOUNI, ELIAS A.

Director

Buy680$0.00$0.00-
May 15, 2026

LIST, TERI

Director

Buy1,699$0.00$0.00-
May 15, 2026

LIST, TERI

Director

Buy680$0.00$0.00-
May 15, 2026

SANDERS, A SHANE

Director

Buy680$0.00$0.00-
May 15, 2026

SPOON, ALAN G

Director

Buy1,699$0.00$0.00-
May 15, 2026

FILLER, LINDA

Director

Buy1,699$0.00$0.00-
May 15, 2026

FILLER, LINDA

Director

Buy680$0.00$0.00-
May 15, 2026

COUCHARA, GEORGEANN

SVP, Human Resources

Sell281$161.91$45,496.71-
May 15, 2026

STEVENS, RAYMOND C

Director

Buy680$0.00$0.00-
May 15, 2026

STEVENS, RAYMOND C

Director

Buy1,699$0.00$0.00-
May 15, 2026

SPOON, ALAN G

Director

Buy680$0.00$0.00-
May 15, 2026

DEWAN, FEROZ

Director

Buy1,699$0.00$0.00-
May 15, 2026

LAMANNA, CHARLES W

Director

Buy680$0.00$0.00-
May 15, 2026

LAMANNA, CHARLES W

Director

Buy1,699$0.00$0.00-
May 1, 2026

SPOON, ALAN G

Director

Sell3,298$0.00$0.00-
May 1, 2026

SPOON, ALAN G

Director

Sell1,358$174.67$237,206.88-
May 1, 2026

SPOON, ALAN G

Director

Buy3,298$71.88$237,060.24-
Apr 24, 2026

DEWAN, FEROZ

Director

Buy188$177.25$33,304.21-
Apr 24, 2026

SPOON, ALAN G

Director

Buy252$177.25$44,724.07-

Insider transactions via Alpha Vantage with SEC EDGAR fallback. Data can include grants, planned sales, and administrative filings; this is not investment advice.

AI Stock Analysis

Unlock an in-depth, balanced bull/bear breakdown of DHR — catalysts, risks, and a plain-language read on the fundamentals.

Upgrade to PRO

Investor Copilot Notebook

Keep a thesis on DHR

Save your buy/watch/avoid rationale, track it over time, and get an AI read on whether the data still backs it up.

Upgrade to PRO

Investment Thesis Timeline

See DHR's full timeline

Earnings surprises, news catalysts, insider activity, and your own notebook events — one dated, classified feed.

Upgrade to PRO
TradingView
Sponsored

Deeper technical charting, indicators, and pattern tools that complement XMarketPro's research.

Open advanced charts

Sponsored partner — XMarketPro may receive compensation if you sign up or purchase through this link. Partner compensation does not influence XMarketPro's analysis, ratings, or research conclusions.

TrendSpider
Sponsored

Automated technical analysis, charting, and pattern recognition for active traders.

Explore automated technical analysis

Sponsored partner — XMarketPro may receive compensation if you sign up or purchase through this link. Partner compensation does not influence XMarketPro's analysis, ratings, or research conclusions.

Seeking Alpha
Sponsored

Another independent research perspective to compare against XMarketPro's own analysis.

Compare with additional research

Sponsored partner — XMarketPro may receive compensation if you sign up or purchase through this link. Partner compensation does not influence XMarketPro's analysis, ratings, or research conclusions.

Interactive Brokers
Sponsored

A well-established U.S. brokerage for investors moving from research into execution.

Explore brokerage options

Sponsored partner — XMarketPro may receive compensation if you sign up or purchase through this link. Partner compensation does not influence XMarketPro's analysis, ratings, or research conclusions.

DHR logo
About Danaher Corporation

Danaher Corporation designs, manufactures, and markets professional, medical, research, and industrial products and services in the United States, China, and internationally. The company operates through Biotechnology, Life Sciences, and Diagnostics segments. The Biotechnology segment provides technologies, consumables, services, and solutions that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, and aseptic fill finish; single-use hardware, consumables, and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services for diagnostic and assay development; and healthcare filtration solutions. The Life Sciences segment provides mass spectrometers; bioanalytical measurement systems; flow cytometry, genomics, lab automation, centrifugation, liquid handling automation instruments, antibodies and reagents, and particle counting and characterization; genome sample preparation; microscopes; protein consumables; filtration products; and genomic medicines, such as custom nucleic acid products, and plasmid DNA, RNA, and proteins under the ABCAM, ALDEVRON, BECKMAN COULTER, GENEDATA, IDT, LEICA MICROSYSTEMS, MOLECULAR DEVICES, PALL, PHENOMENEX, and SCIEX brands. The Diagnostics segment offers clinical instruments, consumables, software, and services that hospitals, physicians' offices, reference laboratories and other critical care settings use to diagnose disease and make treatment decisions. The company was formerly known as Diversified Mortgage Investors, Inc. and changed its name to Danaher Corporation in 1984. Danaher Corporation was incorporated in 1969 and is headquartered in Washington, the District Of Columbia.

Visit danaher.com

Key Statistics

Open
$214.74
Prev Close
$213.56
Day High
$214.34
Day Low
$206.59
Volume
1.95M
Market Cap
$145.36B
P/E Ratio
36.79
EPS
$5.62
Beta
0.80
Dividend Yield
+0.75%
52W High
$242.80
52W Low
$160.93
Analyst Target